论文部分内容阅读
探讨华蟾素肝动脉推注联合热灌注化疗治疗原发性肝癌的临床疗效.[方法]76例原发性肝癌患者随机分为两组,各38例.对照组采取经动脉热灌注化疗后经动脉化疗栓塞(TACE),观察组采取华蟾素肝动脉推注联合热灌注化疗后TACE,均治疗3次,每次间隔1个月.比较两组疗效、不良反应发生率及无进展生存期(PFS)、总生存期(OS).[结果]观察组疾病控制率为63.16%(24/38),高于对照组的41.67% (20/38),但两组之间比较差异无显著性(P>0.05).观察组疼痛发生率为36.84%(14/38),显著低于对照组的63.16%(24/38),且两组相比较差异有显著性(P<0.05).观察组PFS为(12.01±2.89)个月,OS为(19.32±5.48)个月,均显著高于对照组的(10.03±3.00)个月和(15.43±4.82)个月,且两组相比较差异均有显著性(均P0.05).Theincidenceofpainintheobservation groupwas36.84% (14/38),significantlylowerthanthatinthecontrolgroup63.16% (24/38),andtherewas asignificantdifferencebetweenthetwogroups(P<0.05).ThePFSandOSoftheobservationgroupwere (12.01±2.89)monthsand (19.32±5.48)months,whichweresignificantlyhigherthanthoseofthecontrol group(10.03±3.00)monthsand (15.43 ±4.82)months,andthereweresignificantdifferencesbetweenthe twogroups(allP<0.05).[Conclusion]Theanti-tumoreffectofcinobufotalinintrahepaticarteryinjection combinedwithhyperthermicperfusionchemotherapyforprimaryhepatocellularcarcinomaisbetter,thesur-vivaltimeofpatientsisprolongedandthepainisalleviated,whichisworthyofclinicalpromotion.